Mylan NV struck a licensing agreement with Revance Therapeutics Inc. to develop a biosimilar of Allergan Plc’s blockbuster Botox wrinkle treatment.
LabCorp, a leading global life sciences company, announced that its Covance Drug Development business entered into a strategic technology agreement with GlaxoSmithKline plc (GSK).
A Georgia pediatric cardiologist pleaded guilty to wrongfully disclosing info about his patients to an Aegerion sales rep seeking to identify potential new users of an expensive cholesterol drug.
The U.S. Food and Drug Administration approved ZTlido, Sorrento Therapeutics Inc.’s non-opioid painkiller patch for nerve pain related to shingles.
A federal judge dismissed a lawsuit claiming that Coca-Cola Co.’s advertising for Diet Coke misleads people into thinking that consuming the soft drink assists in weight loss, and that it actually causes weight gain.
Viela Bio, based in Gaithersburg, Md., spun out of AstraZeneca Pharmaceuticals’ MedImmune with a Series A financing of up to $250 million.
Gene-editing company Inscripta will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5 million.
The European Medicines Agency is following in the footsteps of the U.S. Food and Drug Administration with plans to help pharma companies win approval for novel Alzheimer’s drugs.
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
Valeant Pharmaceuticals International Inc. announced that its subsidiary entered into an exclusive license agreement with Kaken Pharmaceutical Co. Ltd. to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis.
U.S. health regulators rejected Celgene Corp.’s application seeking approval of a key multiple sclerosis drug due to insufficient data, the company said.